Advances in quantitative biomarker development have accelerated new forms of data-driven
insights for patients with cancer. However, most approaches are limited to a single mode of …

Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

Liver metastasis, the leading cause of colorectal cancer mortality, exhibits a highly
heterogeneous and suppressive immune microenvironment. Here, we sequenced 97 …

With biotechnological advancements, innovative omics technologies are constantly
emerging that have enabled researchers to access multi-layer information from the genome …

The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …

Epithelial–mesenchymal transition (EMT) has been shown to play a critical role in tumor
development from initiation to metastasis. EMT could be regarded as a continuum, with …

Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …

Radiotherapy is a mainstay cancer therapy whose antitumor effects partially depend on T
cell responses. However, the role of Natural Killer (NK) cells in radiotherapy remains …

Abstract Treatment of high-grade serous ovarian cancer (HGSOC) remains challenging.
Although HGSOC can potentially be responsive to immunotherapy owing to endogenous …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …